Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 3 Results

  1. 1
    Peer Reviewed

    The impact of the boxed warning on the duration of use for depot medroxprogesterone acetate.

    Eworuke E; Lee JY; Soule L; Popat V; Moeny DG

    Pharmacoepidemiology and Drug Safety. 2017 Jul; 26(7):827-836.

    OBJECTIVE: The objective of this study was to examine the impact of the Food and Drug Administration's boxed warning on the utilization of depot medroxyprogesterone (DMPA). METHODS: From the IMS Lifelink data (2001-2009), we identified DMPA and oral combined hormonal contraceptive (CHC) users without a prescription claim 6 months before and after the first and last claim. Episodes were defined as all contiguous claims with no more than 90-day DMPA or 30-day CHC between claims. Days' supply (CHC) and 90-day duration (DMPA) was used to determine episodes. We used interrupted time series to evaluate changes in the mean episode length and proportion of episodes >2 years before and after the Food and Drug Administration's November 2004 boxed warning. Stratified analyses by birth cohort were conducted. RESULTS: From 2001 to 2009, 126 528 DMPA and 651 356 CHC episodes were used for segmented regression. For the DMPA cohort, there was an immediate decline in the mean duration (-34.7 days [confidence interval: -45.4 to -24.1]) and episodes >2 years (-1.9% [confidence interval: -2.9% to -1.1%]) after the boxed warning. We did not observe any change in mean duration or episodes >2 years for the CHC cohort. The largest declines in mean duration and proportion >2 years were seen with the oldest women. CONCLUSION: We observed a modest decline in the mean duration and episodes >2 years for DMPA use immediately after the boxed warning not observed among CHC users. In the stratified analysis, we saw declines in the duration of use >2 years in all age groups, except adolescents who continue to use DMPA for longer than 2 years. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
    Add to my documents.
  2. 2
    Peer Reviewed

    Removing the black box warning for depot medroxyprogesterone acetate.

    Kaunitz AM; Grimes DA

    Contraception. 2011 Sep; 84(3):212-3.

    This commentary explains why the Food and Drug Administration (FDA) should remove the black box warning regarding skeletal health on the package labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA). It states that by depriving women of long-term use of this safe, effective product, this black box warning hurts the public health. Copyright © 2011 Elsevier Inc. All rights reserved.
    Add to my documents.
  3. 3

    Public health product catalog 2010.

    United States. Agency for International Development [USAID]; John Snow [JSI]. DELIVER

    Arlington, Virginia, JSI, DELIVER, 2009. [14] p. (USAID Contract No. GPO-I-01-06-00007-00)

    USAID's Public Health Product Catalog 2010 is a catalog of condoms and contraceptives provided by USAID.
    Add to my documents.